Back to Journals » Open Access Journal of Clinical Trials » Volume 3

Phenyramidol in acute conditions of lumbago, integumental pain and musculo-skeletal pain: an open label, noncomparative, multi-center study

Authors Shah H, Shakeel A, Karne N, Patil C, Kewalramani R, Kasodekar V, Dave M

Published 10 May 2011 Volume 2011:3 Pages 27—33


Review by Single anonymous peer review

Peer reviewer comments 2

Hitesh Shah1, Aliya Shakeel2, Narayan Karne3, Chetan Patil4, Rajesh Kewalramani5, Vaibhav Kasodekar6, Malhar Dave7
1Fermenta Biotech Limited, Maharashtra, India; 2Vedic Lifesciences Pvt. Ltd, Mumbai, Maharashtra, India; 3Pune Institute of Accident and Orthopaedics, Pune, Maharashtra, India; 4Muktai Hospital, Nasik, Maharashtra, India; 5General Medical Practitioner, Mumbai, Maharashtra, India; 6Suraj Venture, Mumbai, Maharashtra, India; 7Abhishek Hospital, Vadodara, Gujarat, India

Objective: To assess the safety and efficacy of phenyramidol hydrochloride tablets in acute conditions of lumbago, integumental pain and musculo-skeletal pain.
Methods: This open label, noncomparative, phase IV study recruited adult patients with acute lumbago, integumental pain and musculoskeletal pain who gave written informed consent. Those with elevated liver enzymes, or on analgesics, muscle relaxants, tranquilizers, anti-coagulants, or anti-epileptics were excluded as were pregnant/lactating women. 1 to 2 tablets of 400 mg phenyramidol were given orally 2 to 3 times daily for 3 to 7 days. Safety measures included complete blood count (CBC); liver and renal function tests; electrocardiogram (ECG); global assessments and adverse events. Efficacy measures included change in numerical pain rating scale (NPRS) score and global assessments.
Results: 100 patients completed the study. There were no serious adverse events (SAEs) or deaths. The mean (SEM) reduction in the total white blood cell count [0.27 (0.13) thou/µL, P < 0.05] and the mean (SEM) increase in the serum glutamic pyruvic transaminase (SGPT) level [8.78 (3.40) U/L, P < 0.05] were not clinically significant at the end of the treatment period. Investigators’ assessment of safety was: 80% – excellent, 13% – good, 7% – fair. Tolerability grading by patients was: 53% – excellent, 34% – good, 12% – fair; 1% – poor. Out of the total 12 adverse events (AEs) recorded in 11% patients, 7 were clinical, while 5 were laboratory-related pertaining to increased liver enzymes (5%). The average NPRS score showed an improvement of 68% (P < 0.0001). Investigators assessed 89% patients to have clinically meaningful improvement, patients’ assessment of efficacy was: excellent – 43%; good – 38%; fair – 15%; poor – 4%.
Conclusion: Phenyramidol is effective and well-tolerated in acute lumbago, musculoskeletal pain and integumental pain when given for up to 7 days. However it should be used with caution in patients with liver disease and with drugs known to cause liver damage.

Keywords: phenyramidol, analgesic, liver enzymes, musculoskeletal pain, NPRS

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.